Adel Kardosh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Adel Kardosh has a total of 210 co-authors. Here are the top co-authors by number of shared publications:
- Gordon Brent Mills
Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA
38 shared publications - Amy E. Moran
Oregon Health & Science University 2 Department of Cell, Developmental and Cancer Biology, Knight Cancer Institute Portland, Oregon
36 shared publications - Canping Chen
Department of Biomedical Engineering, Oregon Health & Science University, Portland, Oregon
36 shared publications - Faming Zhao
Department of Biomedical Engineering, Oregon Health & Science University, Portland, Oregon
36 shared publications - Gabriel Mesquita Zangirolani
Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon
36 shared publications - George V. Thomas
Knight Cancer Institute, Oregon Health & Science University, Portland, OR 97239, USA
36 shared publications
Latest Publications
- 1 November 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (31) , 3006-3014
Avatrombopag Versus Placebo for Persistent Chemotherapy-Induced Thrombocytopenia in GI Cancers: The Phase II ACT-GI Trial
PURPOSE: Chemotherapy-induced thrombocytopenia (CIT) is a challenging and common complication of cytotoxic chemotherapy in patients with GI cancers. There is no widely available approved treatment. Avatrombopag is a potent, second-generation oral thrombopoietin receptor agonist promising for CIT management. METHODS: We conducted a multicenter, randomized, double-blind, investigator-initiated US trial of avatrombopag or placebo (1:1) in GI cancer patients with persistent CIT (platelets ≤85 × 10 9 /L on day 1 of a chemotherapy cycle despite adequate time to recover from the prior cycle). The primary end point was successful correction of CIT and prevention of recurrence (defined as recovery of platelets to ≥100 × 10 9 /L, no chemotherapy dose modification/delay, and prevention of CIT recurrence [platelets ≥100 × 109/L] at end of the on-study cycle). RESULTS: The trial was closed to enrollment by the data and safety monitoring board at the planned interim analysis after meeting prespecified stopping criteria for efficacy. Sixteen of 23 patients (70% [95% CI, 47 to 87]) receiving avatrombopag achieved the primary end point versus 4/24 patients (17% [95% CI, 5 to 37]) receiving placebo ( Z = 3.67, P < .001). The median (IQR) platelet count at the end of the on-cycle treatment period was 157 (136-202) × 10 9 /L with avatrombopag versus 72 (68-134) × 10 9 /L with placebo. Adverse events (AEs) and serious AEs occurred in 78% and 17% of patients receiving avatrombopag and 46% and 0% of patients receiving placebo, respectively. No serious AEs were study drug-related. There were no treatment-related AEs leading to death or discontinuation of study drug. CONCLUSION: In this randomized, placebo-controlled trial, avatrombopag was efficacious in the management of persistent CIT in patients with GI cancers. These findings are promising for a common, challenging oncologic complication that prevents delivery of full-dose, on-time, cancer-directed therapy.
- 1 November 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (31) , 3006-3014
Avatrombopag Versus Placebo for Persistent Chemotherapy-Induced Thrombocytopenia in GI Cancers: The Phase II ACT-GI Trial
PURPOSE: Chemotherapy-induced thrombocytopenia (CIT) is a challenging and common complication of cytotoxic chemotherapy in patients with GI cancers. There is no widely available approved treatment. Avatrombopag is a potent, second-generation oral thrombopoietin receptor agonist promising for CIT management. METHODS: We conducted a multicenter, randomized, double-blind, investigator-initiated US trial of avatrombopag or placebo (1:1) in GI cancer patients with persistent CIT (platelets ≤85 × 10 9 /L on day 1 of a chemotherapy cycle despite adequate time to recover from the prior cycle). The primary end point was successful correction of CIT and prevention of recurrence (defined as recovery of platelets to ≥100 × 10 9 /L, no chemotherapy dose modification/delay, and prevention of CIT recurrence [platelets ≥100 × 109/L] at end of the on-study cycle). RESULTS: The trial was closed to enrollment by the data and safety monitoring board at the planned interim analysis after meeting prespecified stopping criteria for efficacy. Sixteen of 23 patients (70% [95% CI, 47 to 87]) receiving avatrombopag achieved the primary end point versus 4/24 patients (17% [95% CI, 5 to 37]) receiving placebo ( Z = 3.67, P < .001). The median (IQR) platelet count at the end of the on-cycle treatment period was 157 (136-202) × 10 9 /L with avatrombopag versus 72 (68-134) × 10 9 /L with placebo. Adverse events (AEs) and serious AEs occurred in 78% and 17% of patients receiving avatrombopag and 46% and 0% of patients receiving placebo, respectively. No serious AEs were study drug-related. There were no treatment-related AEs leading to death or discontinuation of study drug. CONCLUSION: In this randomized, placebo-controlled trial, avatrombopag was efficacious in the management of persistent CIT in patients with GI cancers. These findings are promising for a common, challenging oncologic complication that prevents delivery of full-dose, on-time, cancer-directed therapy.
- 14 October 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
Treatment of Advanced Biliary Tract Cancer: ASCO Living Guideline, Version 2026.1.0
PURPOSE: This living guideline provides recommendations for liquid biopsy and treatment of patients with advanced biliary tract cancer . METHODS: The American Society of Clinical Oncology convened an Expert Panel to conduct a systematic review of relevant studies and develop recommendations for liquid biopsy and systemic therapy for patients with advanced biliary tract cancer. RESULTS: Six studies provided estimates of concordance between liquid biopsy and tissue biopsy. Nine RCTs were included in the evidence base for first-line therapy. One phase III RCT and four phase II RCTs were included in the evidence for second-line chemotherapy. Eleven single studies or reviews supported biomarker-specific second-line therapy recommendations. RECOMMENDATIONS: Testing with broad-based tissue DNA and RNA NGS testing to determine the presence of targetable biomarkers is recommended at the time of diagnosis at any stage. Liquid biopsy with plasma is generally recommended only when tissue biopsy is unavailable. As first-line therapy for patients with pMMR/MSS advanced BTC, immune checkpoint inhibitors (ICIs) plus chemotherapy is recommended. Options for patients with advanced BTC who are not candidates for ICIs are included in the guideline. Pembrolizumab monotherapy is an option for patients with dMMR/MSI-H advanced BTC. For patients with disease progression on first-line treatment and who have no identified biomarkers, FOLFOX with active symptom control, or active symptom control alone are recommended; options for patients who are ineligible for oxaliplatin-based chemotherapy are included in the guideline. Second-line therapy options are recommended for patients with dMMR/MSI-H, IDH1 mutations, FGFR2 fusions or rearrangements, BRAF V600E mutations, HER2 overexpression, RET, NTRK1/2/3, or NRG1 fusions. Additional information is available at https://ascopubs.org/guidelines/living-guidelines
- 14 October 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
Treatment of Advanced Biliary Tract Cancer: ASCO Living Guideline, Version 2026.1.0
PURPOSE: This living guideline provides recommendations for liquid biopsy and treatment of patients with advanced biliary tract cancer . METHODS: The American Society of Clinical Oncology convened an Expert Panel to conduct a systematic review of relevant studies and develop recommendations for liquid biopsy and systemic therapy for patients with advanced biliary tract cancer. RESULTS: Six studies provided estimates of concordance between liquid biopsy and tissue biopsy. Nine RCTs were included in the evidence base for first-line therapy. One phase III RCT and four phase II RCTs were included in the evidence for second-line chemotherapy. Eleven single studies or reviews supported biomarker-specific second-line therapy recommendations. RECOMMENDATIONS: Testing with broad-based tissue DNA and RNA NGS testing to determine the presence of targetable biomarkers is recommended at the time of diagnosis at any stage. Liquid biopsy with plasma is generally recommended only when tissue biopsy is unavailable. As first-line therapy for patients with pMMR/MSS advanced BTC, immune checkpoint inhibitors (ICIs) plus chemotherapy is recommended. Options for patients with advanced BTC who are not candidates for ICIs are included in the guideline. Pembrolizumab monotherapy is an option for patients with dMMR/MSI-H advanced BTC. For patients with disease progression on first-line treatment and who have no identified biomarkers, FOLFOX with active symptom control, or active symptom control alone are recommended; options for patients who are ineligible for oxaliplatin-based chemotherapy are included in the guideline. Second-line therapy options are recommended for patients with dMMR/MSI-H, IDH1 mutations, FGFR2 fusions or rearrangements, BRAF V600E mutations, HER2 overexpression, RET, NTRK1/2/3, or NRG1 fusions. Additional information is available at https://ascopubs.org/guidelines/living-guidelines
- Open Access
Cyclic immunofluorescence platform using photocleavable linkers for direct antibody labeling enables cancer phenotyping
Advances in spatial proteomics through the development of multiplexed immunostaining platforms have facilitated analyses with increasing cellular and molecular granularity. However, currently available approaches are limited by harsh conditions for signal removal, restricting the number of antigens that can be probed in a single specimen without significant alterations to sample quality and structure. Here we present an approach for direct labeling of primary antibodies with fluorophores using a photocleavable linker (PCL) with a polyethylene glycol spacer (PEG) to enable cyclic immunofluorescence (cyCIF) with gentle signal removal conditions. Our innovative approach uses directly labeled primary antibodies to enhance staining specificity and cyclic immunostaining efficiency, while minimizing nonspecific background signal. Additionally, through integration of the PCL, this approach facilitates gentle cleavage of antibody conjugated fluorophore, preserving sample integrity over multiple rounds of staining. Direct PEG-PCL antibody labeling will promote greater multiplexing by minimizing specimen damage and allow for quantitative analyses of cyCIF spatial data. We demonstrate that cyCIF with PEG-PCL conjugated antibodies can be applied across a variety of cancer subtypes to identify and characterize rare neoplastic cell populations in both tumor tissue and fragile peripheral blood specimens.
Open AccessCyclic immunofluorescence platform using photocleavable linkers for direct antibody labeling enables cancer phenotyping
Advances in spatial proteomics through the development of multiplexed immunostaining platforms have facilitated analyses with increasing cellular and molecular granularity. However, currently available approaches are limited by harsh conditions for signal removal, restricting the number of antigens that can be probed in a single specimen without significant alterations to sample quality and structure. Here we present an approach for direct labeling of primary antibodies with fluorophores using a photocleavable linker (PCL) with a polyethylene glycol spacer (PEG) to enable cyclic immunofluorescence (cyCIF) with gentle signal removal conditions. Our innovative approach uses directly labeled primary antibodies to enhance staining specificity and cyclic immunostaining efficiency, while minimizing nonspecific background signal. Additionally, through integration of the PCL, this approach facilitates gentle cleavage of antibody conjugated fluorophore, preserving sample integrity over multiple rounds of staining. Direct PEG-PCL antibody labeling will promote greater multiplexing by minimizing specimen damage and allow for quantitative analyses of cyCIF spatial data. We demonstrate that cyCIF with PEG-PCL conjugated antibodies can be applied across a variety of cancer subtypes to identify and characterize rare neoplastic cell populations in both tumor tissue and fragile peripheral blood specimens.
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S11 from Elevated Tumor-Associated Androgen Receptor Activity Correlates with Poor Immune Infiltration and Immunotherapy Response across Cancer Types
Correlations between AR activity and immune signatures with overlapping genes removed.
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S11 from Elevated Tumor-Associated Androgen Receptor Activity Correlates with Poor Immune Infiltration and Immunotherapy Response across Cancer Types
Correlations between AR activity and immune signatures with overlapping genes removed.
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S15 from Elevated Tumor-Associated Androgen Receptor Activity Correlates with Poor Immune Infiltration and Immunotherapy Response across Cancer Types
AR activity levels are negatively correlated with gene signatures of IFN-γ signaling and TLS in GTEx tissue samples.
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S15 from Elevated Tumor-Associated Androgen Receptor Activity Correlates with Poor Immune Infiltration and Immunotherapy Response across Cancer Types
AR activity levels are negatively correlated with gene signatures of IFN-γ signaling and TLS in GTEx tissue samples.
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Figure 7 from Elevated Tumor-Associated Androgen Receptor Activity Correlates with Poor Immune Infiltration and Immunotherapy Response across Cancer Types
Correlation analysis of AR protein expression with immune cell markers CD45 and CD4 in DSP protein profiling across breast, ovarian, and sarcoma cancer types. Scatter plots show the correlation between AR and (A) CD45 protein expression and (B) CD4 protein expression. Protein expression values were normalized to the standard control probe. C, Representative IHC images of AR and CD4 expression in tumor tissues from two patients with sarcoma. For each marker, the left panels show images at 5× magnification and the right panels show images at 20× magnification. Brown staining indicates positive expression.
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 7 from Elevated Tumor-Associated Androgen Receptor Activity Correlates with Poor Immune Infiltration and Immunotherapy Response across Cancer Types
Correlation analysis of AR protein expression with immune cell markers CD45 and CD4 in DSP protein profiling across breast, ovarian, and sarcoma cancer types. Scatter plots show the correlation between AR and (A) CD45 protein expression and (B) CD4 protein expression. Protein expression values were normalized to the standard control probe. C, Representative IHC images of AR and CD4 expression in tumor tissues from two patients with sarcoma. For each marker, the left panels show images at 5× magnification and the right panels show images at 20× magnification. Brown staining indicates positive expression.
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data 4 from Elevated Tumor-Associated Androgen Receptor Activity Correlates with Poor Immune Infiltration and Immunotherapy Response across Cancer Types
Data for Figure S2B to S2D and S3A, B
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 4 from Elevated Tumor-Associated Androgen Receptor Activity Correlates with Poor Immune Infiltration and Immunotherapy Response across Cancer Types
Data for Figure S2B to S2D and S3A, B
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S18 from Elevated Tumor-Associated Androgen Receptor Activity Correlates with Poor Immune Infiltration and Immunotherapy Response across Cancer Types
AR activity levels are negatively correlated with immune cell infiltration in TME of human PCa evaluated by scRNA-seq.
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S18 from Elevated Tumor-Associated Androgen Receptor Activity Correlates with Poor Immune Infiltration and Immunotherapy Response across Cancer Types
AR activity levels are negatively correlated with immune cell infiltration in TME of human PCa evaluated by scRNA-seq.
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S16 from Elevated Tumor-Associated Androgen Receptor Activity Correlates with Poor Immune Infiltration and Immunotherapy Response across Cancer Types
Overview of AR Activity across 54 GTEx tissue types. Boxplots displaying AR activity ranked in order of decreasing AR activity median among 54 GTEx tissue types.
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S16 from Elevated Tumor-Associated Androgen Receptor Activity Correlates with Poor Immune Infiltration and Immunotherapy Response across Cancer Types
Overview of AR Activity across 54 GTEx tissue types. Boxplots displaying AR activity ranked in order of decreasing AR activity median among 54 GTEx tissue types.